Abstract
Therapeutic Effect of Ambroxol Hydrochloride in Conjunction with Azithromycin in Treating Mycoplasma pneumoniae Pneumonia in Children
Department of Radiology, 1Department of Paediatric, First People’s Hospital of Longquanyi District, Chengdu, Sichuan Province 610100, China
Correspondence Address:
Demao Mao, Department of Radiology, First People’s Hospital of Longquanyi District, Chengdu, Sichuan Province 610100, China, E-mail: mao15008455148@163.com
To observe the therapeutic effect and changes in chest computed tomography signs in treating Mycoplasma pneumoniae pneumonia in children with ambroxol hydrochloride in conjunction with azithromycin. From November 2021 to November 2023, a total of 70 children diagnosed with Mycoplasma pneumoniae pneumonia were admitted to our hospital. These children were randomly assigned to either the control group or the observation group, with equal distribution of 35 cases in each group. Oral azithromycin was administered to the control group for 5 consecutive days, while the observation group received a combined treatment of azithromycin for 5 consecutive days and ambroxol hydrochloride for 7 consecutive days. A comparison was made between the two groups in terms of the time needed for temperature recovery, cough resolution, and disappearance of lung rales. Additionally, the comparison of various chest computed tomography signs before and after 7 d of treatment was conducted between the two groups. The incidence of adverse reactions during the treatment period was also recorded and compared. The observation group showed a remarkably shorter duration for temperature recovery, cough resolution, and disappearance of lung rales compared to the control group (p<0.05). Additionally, the overall treatment efficacy rate was notably higher in the observation group, reaching 94.29 %, and significantly surpassed the control group’s rate of 77.14 % (p<0.05). During the treatment period, both groups of patients experienced adverse reactions such as rash, nausea/vomiting, and abdominal pain, with no remarkable disparity in the incidence of adverse reactions between the control group (17.14 %) and the observation group (20.00 %) (p>0.05). The combination therapy of ambroxol hydrochloride and azithromycin offers substantial therapeutic benefits for treating Mycoplasma pneumoniae pneumonia in children. It effectively reduces the duration of symptoms and signs, facilitates the recovery of lung lesions, and poses no notable risk of adverse reactions.
Full-Text | PDF